Although there is not any reports of MEF2C::SS18L1 in hematologic tumors at present, the presence of recurrent MEF2C::SS18 fusions in MSA suggests the importance and specificity of this fusion in pathogenesis of malignant tumor. This evidence concerns the gene MEF2C and cancer.